Metabolomics in chronic kidney disease

Clinica Chimica Acta

Volumn 422, Issue , 2013, Pages 59-69

  Zhao, Ying Yong ^a  

^a NORTHWEST UNIVERSITY   (China)

Author keywords

Chronic kidney disease; Mechanism; Metabolic profiling; Metabolomics; Metabonomics; Systems biology

Indexed keywords

6 N,N' DIMETHYLARGININE; AMINO ACID; ASPARTIC ACID; AZELAIC ACID; CITRULLINE; CREATININE; CYSTATIN C; GAMMA BUTYROBETAINE; GLUCURONIDE; INTERMEDIATE DENSITY LIPOPROTEIN; KYNURENINE; LEUCINE; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPID; MUCIC ACID; PHENYLALANINE; PHOSPHOLIPID; PHYTOSPHINGOSINE; POLYOL; SPHINGANINE; SPHINGOMYELIN; SUGAR ACID; TRANSFORMING GROWTH FACTOR BETA1; TRYPTOPHAN; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID;

BIOACCUMULATION; BLOOD LEVEL; CAPILLARY ELECTROPHORESIS; CHEMOMETRIC ANALYSIS; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL RESEARCH; DATA ANALYSIS; DIABETIC NEPHROPATHY; DISEASE ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; LIPID METABOLISM; MASS FRAGMENTOGRAPHY; METABOLOMICS; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINE LEVEL;

ANIMALS; HUMANS; METABOLOME; METABOLOMICS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84877887630     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.03.033     Document Type: Review

References (97)

1. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005, 67:2089-2100.
2. Lameire N., Jager K., Van Biesen W., de Bacquer D., Vanholder R. Chronic kidney disease: a European perspective. Kidney Int 2005, 99:S30-S38.
3. Levey A.S., Atkins R., Coresh J., et al. Chronic kidney disease as a global public health problem: approaches and initiatives-a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007, 72:247-259.
4. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-β pathway. Kidney Int 2006, 70:1914-1919.
5. Yu H.T. Progression of chronic renal failure. Arch Intern Med 2003, 163:1417-1429.
6. Nangaku M. Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure. Intern Med 2004, 43:9-17.
7. Meguid El, Nahas A., Bello A.K. Chronic kidney disease: the global challenge. Lancet 2005, 365:331-340.
8. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266.
9. International Federation of Clinical Chemistry and Laboratory Medicine, Working Group on Standardization of Glomerular Filtration Rate Assessment (WG-GFRA), Panteghini M., Myers G.L., Miller W.G., Greenberg N. The importance of metrological traceability on the validity of creatinine measurement as an index of renal function. Clin Chem Lab Med 2006, 44:1287-1292.
10. Urbschat A., Obermüller N., Haferkamp A. Biomarkers of kidney injury. Biomarkers 2011, 16:S22-S30.
11. Perco P., Pleban C., Kainz A., et al. Protein biomarkers associated with acute renal failure and chronic kidney disease. Eur J Clin Invest 2006, 36:753-763.
12. Prunotto M., Ghiggeri G.M., Candiano G., Lescuyer P., Hochstrasser D., Moll S. Urinary proteomics and drug discovery in chronic kidney disease: a new perspective. J Proteome Res 2011, 10:126-132.
13. Mullen W., Delles C., Mischak H. Urinary proteomics in the assessment of chronic kidney disease. Curr Opin Nephrol Hypertens 2011, 20:654-661.
14. Prunotto M., Ghiggeri G.M., Bruschi M., et al. Renal fibrosis and proteomics: current knowledge and still key open questions for proteomic investigation. J Proteomics 2011, 74:1855-1870.
15. Rule A.D., Bergstralh E.J., Slezak J.M., Bergert J., Larson T.S. Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int 2006, 69:399-405.
16. Nicholson J.K., Lindon J.C., Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-1189.
17. Horning E.C., Horning M.G. Metabolic profiles: gas-phase methods for analysis of metabolites. Clin Chem 1971, 17:802-809.
18. Nicholson J.K., Connelly J., Lindon J.C., et al. Metabolomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002, 1:153-161.
19. Fiehn O. Metabolomics-the link between genotypes and phenotypes. Plant Mol Biol 2002, 48:155-171.
20. Davis B. Growing pains for metabolomics. Scientist 2005, 19:25-28.
21. Griffin J.L., Shockcor J.P. Metabolic profiles of cancer cells. Nat Rev Cancer 2004, 4:551-561.
22. Dunn W.B., Bailey N.J., Johnson H.E. Measuring the metabolome: current analytical technologies. Analyst 2005, 130:606-625.
23. 1H-NMR-based metabolomics. Expert Rev Mol Diagn 2006, 6:717-731.
24. Min J.Z., Yano H., Matsumoto A., et al. Simultaneous determination of polyamines in human nail as 4-(N,N-dimethylaminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole derivatives by nano-flow chip LC coupled with quadrupole time-of-flight tandem mass spectrometry. Clin Chim Acta 2011, 412:98-106.
25. Kawanishi H., Toyo'oka T., Ito K., et al. Hair analysis of histamine and several metabolites in C3H/HeNCrj mice by ultra performance liquid chromatography with electrospray ionization time-of-flight mass spectrometry (UPLC-ESI-TOF-MS): influence of hair cycle and age. Clin Chim Acta 2007, 378:122-127.
26. Morris H.R., Paxton T., Dell A., et al. High sensitivity collisionally-activated decomposition tandem mass spectrometry on a novel quadrupole/orthogonal-acceleration time-of-flight mass spectrometer. Rapid Commun Mass Spectrom 1996, 10:889-896.
27. Yao M., Ma L., Duchoslav E., Zhu M. Rapid screening and characterization of drug metabolites using multiple ion monitoring dependent product ion scan and postacquisition data mining on a hybrid triple quadrupole-linear ion trap mass spectrometer. Rapid Commun Mass Spectrom 2009, 23:1683-1693.
28. Le Blanc J.C., Hager J.W., Ilisiu A.M., Hunter C., Zhong F., Chu I. Unique scanning capabilities of a new hybrid linear ion trap mass spectrometer (Q TRAP) used for high sensitivity proteomics applications. Proteomics 2003, 3:859-869.
29. Syka J.E., Marto J.A., Bai D.L., et al. Novel linear quadrupole ion trap/FT mass spectrometer: performance characterization and use in the comparative analysis of histone H3 post-translational modifications. J Proteome Res 2004, 3:621-626.
30. Wrona M., Mauriala T., Bateman K.P., Mortishire-Smith R.J., O'Connor D. 'All-in-One' analysis for metabolite identification using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry with collision energy switching. Rapid Commun Mass Spectrom 2005, 19:2597-2602.
31. E with mass defect filtering for in vitro and in vivo metabolite identification. Rapid Commun Mass Spectrom 2007, 21:1485-1496.
32. Rainville P.D., Stumpf C.J., Shockcor J.P., Plumb R.S., Nicholson J.K. Novel application of reversed-phase UPLC-oaTOFMS for lipid analysis in complex biological mixture: a new tool for lipidomics. J Proteome Res 2007, 6:552-558.
33. n. Bioanalysis 2012, 4:713-723.
34. Elevated Energy data collection technique: determination and pharmacokinetics, tissue distribution and biliary excretion study of ergone in rat. J Sep Sci 2012, 35:1619-1629.
35. Zhao Y.Y., Zhang L., Feng Y.L., et al. Pharmacokinetics of 2,3,5,4'-tetrahydroxystilbene-2-O-β-d-glucoside in rat using ultra-performance LC-quadrupole TOF-MS. J Sep Sci 2013, 36:863-871.
36. Werner E., Heilier J.F., Ducruix C., Ezan E., Junot C., Tabet J.C. Mass spectrometry for the identification of the discriminating signals from metabolomics: current status and future trends. J Chromatogr B 2008, 871:143-163.
37. Zhang A., Sun H., Yan G., Han Y., Ye Y., Wang X. Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid-chromatography coupled with high-definition mass spectrometry. Clin Chim Acta 2013, 418:86-90.
38. Zheng S., Yu M., Lu X., et al. Urinary metabonomic study on biochemical changes in chronic unpredictable mild stress model of depression. Clin Chim Acta 2010, 411:204-209.
39. Schleicher R.L., Encisco S.E., Chaudhary-Webb M., Paliakov E., McCoy L.F., Pfeiffer C.M. Isotope dilution ultra performance liquid chromatography-tandem mass spectrometry method for simultaneous measurement of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3 and 3-epi-25-hydroxyvitamin D3 in human serum. Clin Chim Acta 2011, 412:1594-1599.
40. Zhao Y.Y., Qin X.Y., Cheng X.L., et al. Rapid resolution liquid chromatography-mass spectrometry and high-performance liquid chromatography-fluorescence detection for metabolism and pharmacokinetic studies of ergosta-4,6,8(14),22-tetraen-3-one. Anal Chim Acta 2010, 675:199-206.
41. E. J Pharm Biomed 2013, 81-82:202-209.
42. Zhao Y.Y., Cheng X.L., Liu R., et al. Pharmacokinetics of ergosterol in rats using rapid resolution liquid chromatography-atmospheric pressure chemical ionization multi-stage tandem mass spectrometry and rapid resolution liquid chromatography/tandem mass spectrometry. J Chromatogr B 2011, 879:1945-1953.
43. Zhang T., Wu X., Yin M., et al. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. Clin Chim Acta 2012, 413:861-868.
44. Tsutsui H., Maeda T., Min J.Z., et al. Biomarker discovery in biological specimens (plasma, hair, liver and kidney) of diabetic mice based upon metabolite profiling using ultra-performance liquid chromatography with electrospray ionization time-of-flight mass spectrometry. Clin Chim Acta 2011, 412:861-872.
45. Zhao Y.Y., Cheng X.L., Wei F., Han X.Q., Xiao X.Y., Lin R.C. Pharmacokinetics, bioavailability, and metabolism of 2,3,5,4'-tetrahydroxystilbene-2-O-β-d-glucoside in rats by ultra performance liquid chromatography-quadrupole time-of-flight mass spectrometry and high performance liquid chromatography-ultraviolet detection. J Liq Chromatogr Relat Technol 2013, 36:717-730.
46. Gidman E., Goodacre R., Emmett B., Smith A.R., Gwynn-Jones D. Investigating plant-plant interference by metabolic fingerprinting. Phytochemistry 2003, 63:705-710.
47. Johnson H.E., Broadhurst D., Goodacre R., Smith A.R. Metabolic fingerprinting of salt-stressed tomatoes. Phytochemistry 2003, 62:919-928.
48. Harrigan G.G., LaPlante R.H., Cosma G.N., et al. Application of high-throughput Fourier-transform infrared spectroscopy in toxicology studies: contribution to a study on the development of an animal model for idiosyncratic toxicity. Toxicol Lett 2004, 146:197-205.
49. Trygg J., Holmes E., Lundstedt T. Chemometrics in metabonomics. J Proteome Res 2007, 6:469-479.
50. 1H nuclear magnetic resonance spectroscopy and principal component analysis. Prog Biochem Biophys 2008, 35:1142-1153.
51. Woo H.M., Kim K.M., Choi M.H., et al. Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin Chim Acta 2009, 400:63-69.
52. Zhao Y.Y., Cheng X.L., Wei F., et al. Serum metabonomics study of adenine-induced chronic renal failure rat by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Biomarkers 2012, 17:48-55.
53. Zhao Y.Y., Cheng X.L., Wei F., Bai X., Lin R.C. Effect of ergosta-4,6,8(14),22-tetraen-3-one (ergone) on adenine-induced chronic renal failure rat: a serum metabonomics study based on ultra performance liquid chromatography/high-sensitivity mass spectrometry coupled with MassLynx i-FIT algorithm. Clin Chim Acta 2012, 413:1438-1445.
54. Kikuchi K., Itoh Y., Tateoka R., Ezawa A., Murakami K., Niwa T. Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spectrometry. J Chromatogr B 2010, 878:1662-1668.
55. Kikuchi K., Itoh Y., Tateoka R., Ezawa A., Murakami K., Niwa T. Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J Chromatogr B 2010, 878:2997-3002.
56. Ma C., Bi K., Su D., et al. Serum and kidney metabolic changes of rat nephrotoxicity induced by Morning Glory Seed. Food Chem Toxicol 2010, 48:2988-2993.
57. Jia L., Wang C., Kong H., Cai Z., Xu G. Plasma phospholipid metabolic profiling and biomarkers of mouse IgA nephropathy. Metabolomics 2006, 2:95-104.
58. Zhao Y.Y., Feng Y.L., Bai X., Tan X.J., Lin R.C., Mei Q. Ultra performance liquid chromatography-based metabonomic study of therapeutic effect of the surface layer of Poria cocos on adenine-induced chronic kidney disease provides new insight into anti-fibrosis mechanism. PLoS One 2013, 8:e59617.
59. Zhao Y.Y., Liu J., Cheng X.L., Bai X., Lin R.C. Urinary metabonomics study on biochemical changes in an experimental model of chronic renal failure by adenine based on UPLC Q-TOF/MS. Clin Chim Acta 2012, 413:642-649.
60. E data collection technique. Process Biochem 2012, 47:1980-1987.
61. Ma C., Bi K., Zhang M., et al. Metabonomic study of biochemical changes in the urine of Morning Glory Seed treated rat. J Pharm Biomed Anal 2010, 53:559-566.
62. Ma C., Bi K., Zhang M., et al. Toxicology effects of Morning Glory Seed in rat: a metabonomic method for profiling of urine metabolic changes. J Ethnopharmacol 2010, 130:134-142.
63. Taylor S.L., Ganti S., Bukanov N.O., et al. A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease. Am J Physiol Renal Physiol 2010, 298:F909-F922.
64. E data collection technique. Biomarkers 2012, 17:721-729.
65. E-based metabonomics for adenine-induced changes in metabolic profiles of rat faeces and intervention effects of ergosta-4,6,8(14),22-tetraen-3-one. Chem Biol Interact 2013, 301:31-38.
66. E. J Proteome Res 2013, 12:692-703.
67. Kim T.H., Ahn M.Y., Lim H.J., et al. Evaluation of metabolomic profiling against renal toxicity in Sprague-Dawley rats treated with melamine and cyanuric acid. Arch Toxicol 2012, 86:1885-1897.
68. Yokozawa T., Zheng P.D., Oura H., Koizumi F. Animal model of adenine-induced chronic renal failure in rats. Nephron 1986, 44:230-234.
69. Wikoff W.R., Nagle M.A., Kouznetsova V.L., Tsigelny I.F., Nigam S.K. Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). J Proteome Res 2011, 10:2842-2851.
70. 1H NMR spectroscopy analysis of metabolites in the kidneys provides new insight into pathophysiological mechanisms: applications for treatment with Cordyceps sinensis. Nephrol Dial Transplant 2012, 27:556-565.
71. Lu X., Xiong Z., Li J., Zheng S., Huo T., Li F. Metabonomic study on 'Kidney-Yang Deficiency syndrome' and intervention effects of Rhizoma Drynariae extracts in rats using ultra performance liquid chromatography coupled with mass spectrometry. Talanta 2011, 83:700-708.
72. 1H NMR-based metabonomic analysis of metabolic profiling in diabetic nephropathy rats induced by streptozotocin. Am J Physiol Renal Physiol 2011, 300:F947-F956.
73. Zhao L., Gao H., Zhao Y., Lin D. Metabonomic analysis of the therapeutic effect of Zhibai Dihuang Pill in treatment of streptozotocin-induced diabetic nephropathy. J Ethnopharmacol 2012, 142:647-656.
74. Zhao T., Zhang H., Zhao T., et al. Intrarenal metabolomics reveals the association of local organic toxins with the progression of diabetic kidney disease. J Pharm Biomed Anal 2012, 60:32-43.
75. Jia L., Chen J., Yin P., Lu X., Xu G. Serum metabonomics study of chronic renal failure by ultra performance liquid chromatography coupled with Q-TOF mass spectrometry. Metabolomics 2008, 4:183-189.
76. Rhee E.P., Souza A., Farrell L., et al. Metabolite profiling identifies markers of uremia. J Am Soc Nephrol 2010, 21:1041-1051.
77. Sato E., Kohno M., Yamamoto M., et al. Metabolomic analysis of human plasma from haemodialysis patients. Eur J Clin Invest 2011, 41:241-255.
78. Choi J.Y., Yoon Y.J., Choi H.J., et al. Dialysis modality-dependent changes in serum metabolites: accumulation of inosine and hypoxanthine in patients on haemodialysis. Nephrol Dial Transplant 2011, 26:1304-1313.
79. Dunn W.B., Summers A., Brown M., et al. Proof-of-principle study to detect metabolic changes in peritoneal dialysis effluent in patients who develop encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2012, 27:2502-2510.
80. Toyohara T., Akiyama Y., Suzuki T., et al. Metabolomic profiling of uremic solutes in CKD patients. Hypertens Res 2010, 33:944-952.
81. Toyohara T., Suzuki T., Morimoto R., et al. SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol 2009, 20:2546-2555.
82. Schefold J.C., Zeden J.P., Fotopoulou C., et al. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant 2009, 24:1901-1908.
83. Jia L.W., Wang C., Zhao S.M., Lu X., Xu G.W. Metabolomic identification of potential phospholipid biomarkers for chronic glomerulonephritis by using high performance liquid chromatography-mass spectrometry. J Chromatogr B 2007, 860:134-140.
84. de Gómez Dumm N.T., Giammona A.M., Touceda L.A., Raimondi C. Lipid Abnormalities in chronic renal failure patients undergoing hemodiaysis. Medicina (B Aires) 2001, 61:142-146.
85. Kaori H., Hiroyuki S., Takako H., et al. Use of serum and urine metabolome analysis for the detection of metabolic changes in patients with stage 1-2 chronic kidney disease. Nephro-Urol Mon 2011, 3:164-171.
86. 1H-NMR-spectroscopy. Clin Transl Sci 2012, 5:379-385.
87. Psihogios N.G., Kalaitzidis R.G., Dimou S., Seferiadis K.I., Siamopoulos K.C., Bairaktari E.T. Evaluation of tubulointerstitial lesions' severity in patients with glomerulonephritides: an NMR-based metabonomic study. J Proteome Res 2007, 6:3760-3770.
88. Duan H., Guan N., Wu Y., Zhang J., Ding J., Shao B. Identification of biomarkers for melamine-induced nephrolithiasis in young children based on ultra high performance liquid chromatography coupled to time-of-flight mass spectrometry (U-HPLC-Q-TOF/MS). J Chromatogr B 2011, 879:3544-3550.
89. Goek O.N., Döring A., Gieger C., et al. Serum metabolite concentrations and decreased GFR in the general population. Am J Kidney Dis 2012, 60:197-206.
90. Sui W., Li L., Che W., et al. A proton nuclear magnetic resonance-based metabonomics study of metabolic profiling in immunoglobulin a nephropathy. Clinics (Sao Paulo) 2012, 67:363-373.
91. Atzori L., Mussap M., Noto A., et al. Clinical metabolomics and urinary NGAL for the early prediction of chronic kidney disease in healthy adults born ELBW. J Matern Fetal Neonatal Med 2011, S2:40-43.
92. Zhang J., Yan L., Chen W., et al. Metabonomics research of diabetic nephropathy and type 2 diabetes mellitus based on UPLC-oaTOF-MS system. Anal Chim Acta 2009, 650:16-22.
93. Hirayama A., Nakashima E., Sugimoto M., et al. Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy. Anal Bioanal Chem 2012, 404:3101-3109.
94. Han L.D., Xia J.F., Liang Q.L., et al. Plasma esterified and non-esterified fatty acids metabolic profiling using gas chromatography-mass spectrometry and its application in the study of diabetic mellitus and diabetic nephropathy. Anal Chim Acta 2011, 689:85-91.
95. van der Kloet F.M., Tempels F.W., Ismail N., et al. Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics 2012, 8:109-119.
96. Mäkinen V.P., Tynkkynen T., Soininen P., et al. Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study). J Proteome Res 2012, 11:1782-1790.
97. Mäkinen V.P., Tynkkynen T., Soininen P., et al. Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study). Metabolomics 2012, 8:369-375.